title: Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma.
authors.affiliation: Basking Ridge Medical Oncology Service; and Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York Presbyterian Hospital, Department of Medicine, New York, NY, USA. Electronic address: hamlinp@mskcc.org.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Hamlin
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D000069461:Bendamustine Hydrochloride; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D000069283:Rituximab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; C543332:obinutuzumab